Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Monotherapy or in combination w/ MTX for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to ≥1 DMARDs.
Patients w/ chronic infection, history of recurrent infection, or known risk factors for infection. Do not initiate treatment w/ risankizumab in patients w/ clinically important active infection until it resolves or is adequately treated. Evaluate for TB prior to initiating treatment. Monitor for signs & symptoms of active TB. Patients should not receive live vaccines during treatment & for at least 21 wk after treatment. Wait at least 4 wk prior to starting treatment in patient who has received live vaccination. If serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately & appropriate therapy initiated. Women of childbearing potential should use an effective method of contraception during treatment & for at least 21 wk after treatment. Preferable to avoid during pregnancy. A decision should be made whether to discontinue/abstain from risankizumab therapy in a breast-feeding woman.
Sign Out
